{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T13:20:10Z","timestamp":1765891210677,"version":"3.48.0"},"reference-count":42,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Key Clinical Specialty Construction Project"},{"name":"High-Level Clinical Key Specialty"},{"name":"Central Department of Finance","award":["Z155080000004"],"award-info":[{"award-number":["Z155080000004"]}]},{"name":"Guangzhou Municipal People\u2019s Livelihood Science and Technology Research Program Project","award":["201803010096"],"award-info":[{"award-number":["201803010096"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Policy and Practice"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/20523211.2025.2567960","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:17:49Z","timestamp":1762345069000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive assessment of 5 interleukin inhibitors for the treatment of psoriasis: scientific guidance based on drug selection recommendations for Chinese medical institutions"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9261-0718","authenticated-orcid":false,"given":"Jia-Xin","family":"Zhang","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangzhou, People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Wei","family":"Li","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangzhou, People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Kun","family":"Qiu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangzhou, People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha","family":"Lai","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangzhou, People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2546161"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19509"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18851"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16724"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.12.070"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2018.01038"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.35541\/cjd.20210643"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.35541\/cjd.20220839"},{"key":"e_1_3_4_11_1","unstructured":"Corporation N. P. (2025). COSENTYX\u00ae (secukinumab) injection for subcutaneous use. U.S. Food and Drug Administration."},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.6039\/j.issn.1001-0408.2021.22.23"},{"key":"e_1_3_4_13_1","unstructured":"Eli Lilly and Company. (2016). TALTZ\u00ae (ixekizumab) injection for subcutaneous use. U.S. Food and Drug Administration."},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.07.087"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2350760"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.563"},{"key":"e_1_3_4_17_1","unstructured":"ICH I. C. o. H. (1994). ICH harmonised tripartite guideline: Clinical safety data management \u2013 Definitions and standards for expedited reporting E2A."},{"key":"e_1_3_4_18_1","unstructured":"Janssen Biotech I. (2025a). STELARA\u00ae (ustekinumab) injection for subcutaneous or intravenous use. U.S. Food and Drug Administration."},{"key":"e_1_3_4_19_1","unstructured":"Janssen Biotech I. (2025b). TREMFYA\u00ae (guselkumab) injection for subcutaneous use. U.S. Food and Drug Administration."},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.04.014"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15750"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60725-4"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.S499848"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.19540\/j.cnki.cjcmm.20220315.503"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.139"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2015.02.002"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0579-y"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0800-7"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0917-3"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.23736\/s2784-8671.20.06789-9"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14508"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14507"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12989"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.47102\/annals-acadmedsg.2023367"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2198622"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19018"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0359-0"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2023.59.3.3419557"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312793"},{"key":"e_1_3_4_40_1","unstructured":"Sun Pharmaceutical Industries I. (2018). ILUMYA\u00ae (tildrakizumab-asmn) injection for subcutaneous use. U.S. Food and Drug Administration."},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.3390\/children11080892"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.3870\/j.issn.1004-0781.2023.04.001"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14795"}],"container-title":["Journal of Pharmaceutical Policy and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/20523211.2025.2567960","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T13:16:23Z","timestamp":1765890983000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/20523211.2025.2567960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/20523211.2025.2567960"],"URL":"https:\/\/doi.org\/10.1080\/20523211.2025.2567960","relation":{},"ISSN":["2052-3211"],"issn-type":[{"type":"electronic","value":"2052-3211"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=jppp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=jppp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-04-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2567960"}}